What Happened
Carl Mancini, a licensed pharmacist employed by a Connecticut company that compounded home and hospice care intravenous infusions, tampered with narcotic vials intended for pain-management patients.
As part of his duties, Mancini formulated infusions of hydromorphone hydrochloride and morphine sulfate pentahydrate at the correct concentration for specific patients pursuant to physician orders. Between approximately January and June 2019, he accessed a secure area of his workplace, used a syringe to withdraw narcotics from vials meant for patient infusions, and reinjected saline so the vials would appear untouched. To hide the tampering, Mancini used specialized crimping tools to reseal the vials before returning them to the secure storage area.
Laboratory testing of a sample of the tampered vials found that virtually all of the active drug had been removed and replaced with saline; investigators determined Mancini had tampered with dozens of vials through the scheme. He waived indictment and pleaded guilty in New Haven federal court on December 13, 2019, to tampering with a consumer product, facing a maximum of 10 years in prison.
What Went Wrong
A single pharmacist with unsupervised access to a secure compounding area was able to tamper with dozens of vials over roughly six months before detection. Key failures included:
- No routine potency or weight testing of returned or in-stock compounded narcotic vials, allowing repeated tampering to go undetected for months.
- A single pharmacist had unmonitored, solo access to the secure narcotics area with no second-person verification of compounding activity.
- Tamper-evident vial seals were not inspected closely enough to catch resealing with specialized crimping tools.
- No reconciliation between the volume of narcotics ordered into the facility and the volume actually compounded and shipped to patients.
How It Could Have Been Prevented
- Require two-person verification for compounding and handling of controlled-substance infusions in home-infusion and hospice pharmacies.
- Randomly sample and lab-test compounded narcotic vials for potency to catch dilution before it reaches patients.
- Inspect vial seals under magnification or with tamper-detection technology capable of identifying resealed crimps.
- Reconcile controlled-substance purchase volumes against compounding logs and patient shipments on a recurring schedule, not just at annual inventory.
- Rotate or randomize which staff access secure narcotics storage to reduce the window for undetected solo tampering.
Related Guidance
- Tough Issues — High-risk scenarios with annotated SQL for analyzing dispense-to-administer gaps.
- Pharmacist's Corresponding Responsibility — The pharmacist's legal duty to ensure controlled substance handling is legitimate.
- 15 Red Flags of Drug Diversion — Behavioral and transactional indicators including inventory irregularities.
- Pharmacy Diversion Prevention Checklist — Pharmacy self-assessment covering compounding and dispensing controls.
- Employee Screening & Fitness for Duty — DEA screening requirements (21 C.F.R. §1301.90) and pre-employment vetting for staff with controlled substance access.